Araştırma Makalesi
BibTex RIS Kaynak Göster

Investigation of Functional Change of Submandibular Glands in Patients Re-ceiving High-Dose Radioactive Iodine Treatment for Dry Mouth

Yıl 2023, , 625 - 630, 31.12.2023
https://doi.org/10.35440/hutfd.1268830

Öz

Kaynakça

  • 1. Moffat AK, Apajee J, Pratt NL, Blacker N, Le Blanc VT, Roughead EE. Use of medicines associated with dry mouth and dental visits in an Australian cohort. Aust Dent J. 2020;65(3):189-195.
  • 2. Scully C, Felix DH. Oral medicine update for the dental practi-tioner: dry mouth and disorders of salivation. Br Dent J. 2005;199(7):423-427.
  • 3. Fox PC. Differentiation of dry mouth etiology. Adv Dent Res. 1996;10:13-16.
  • 4. Myers N, Ferris R. Salivary Gland Disorders. New York: Spring-er Business Media; 2007. p. 2-16.
  • 5. Sonkaya E, Akbıyık SY, Bakır EP, Bakır Ş. Posterior Direkt Restorasyonlarda Nerede Başarısızlık Yaşıyoruz? Düzce Ün-iversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2021;11(2):242-249.
  • 6. Eratilla V, Kaplan İ. The effect of age on the severity of dry mouth occurring in patients receiving high dose radioactive io-dine treatment. J Health Sci Med. 2023;6(4):775-779.
  • 7. Eratilla V, Kaplan İ. Investigating the Effect of the Time Elapsed after Treatment on the Severity of Dry Mouth in Pa-tients Experiencing Dry Mouth due to Head and Neck Cancer Treatment. Mod Res Dent. 2023;7(5):777-782.
  • 8. Joanna NDY, Thomson WM. Dry mouth–an overview. Singa-pore Dent J. 20215;36(1):12-17.
  • 9. Haynes S. Medications That Cause Dry Mouth. Digestion. 2022.
  • 10. Scully C, Felix DH. Oral medicine—update for the dental prac-titioner: dry mouth and disorders of salivation. Br Dent J. 2005;199(7):423-427.
  • 11. Eratilla V. Investigation of Parotid Gland Function Changes Caused by Dry Mouth in Patients Receiving High-Dose Radio-active Iodine Treatment. J Oral Health Dent Sci. 2021;10(2):66-74.
  • 12. Su N, Marek CL, Ching V, Grushka M. Caries prevention for patients with dry mouth. J Can Dent Assoc. 2011;77(b85):1-8.
  • 13. De Jong SA. Thyroid cancer: A comprehensive guide to clinical management. Arch Pathol Lab Med. 2000;124(9):1391.
  • 14. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radi-ol). 2007;19(1):83-86.
  • 15. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition, and treatment. J Am Dent Assoc. 2003;134:61-69.
  • 16. Dodds MW, Johnson DA, Yeh CK. Health benefits of saliva: a review. J Dent Res. 2005;(33):223-233.
  • 17. Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. BMC Oph-thalmol. 2020;20(1):1-8.
  • 18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Man-agement Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid As-sociation Guidelines Task Force on Thyroid Nodules and Dif-ferentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
  • 19. Diamond-Rossi SA, Jonklaas J, Jensen RE, Kuo C, Stearns S, Esposito G, et al. Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer. J Cancer Surviv. 2020;14(6):847-857.
  • 20. Goswami S, Peipert BJ, Mongelli MN, Kurumety SK, Hele-nowski IB, Yount SE, Sturgeon C. Clinical factors associated with worse quality-of-life scores in United States thyroid can-cer survivors. Surgery. 2019;166(1):69- 74.
  • 21. Mols F, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a nor-mative sample: Results from the PROFILES Registry. Head Neck. 2018;40(10):2235–2245.
  • 22. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of sali-vary gland dysfunction in patients with thyroid cancer after ra-dioiodine treatment. Clin Nucl Med. 2002;27(11):767-771.
  • 23. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27(10):1519-27.
  • 24. Luster M, et al. Guidelines for radioiodine therapy of differen-tiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.
  • 25. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerosto-mia symptoms. Thyroid. 2013;23(5):609–616.
  • 26. Jonklaas J, Wang H, Esposito G. Salivary function after radio-iodine therapy: poor correlation between symptoms and sali-vary scintigraphy. Front Endocrinol (Lausanne). 2015;6:100.
  • 27. Epstein JB, Stevenson-Moore P, Scully C. Management of xerostomia. J Can Dent Assoc. 1992;58:140-143.
  • 28. Epstein JB, van der Meji EH, Lunn R, Steverson-Moore P. Ef-fects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol En-dod. 1996;82:268-275.
  • 29. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:28-46.
  • 30. Walter MA, Turtschi CP, Schindler C, Minnig P, Müller-Brand J, Müller B. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med. 2007;48:1620-1625.
  • 31. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1992;33:2214-2221.
  • 32. Husson O, Mols F, Oranje WA, Haak HR, Nieuwlaat WA, Ne-tea-Maier RT, et al. Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: results of the PROFILES registry. Psycho-Oncology. 2014;23(8):946-952..
  • 33. Goldfarb M, Casillas J. Unmet information and support needs in newly diagnosed thyroid cancer: comparison of adoles-cents/young adults (AYA) and older patients. J Cancer Surviv. 2014;8(3):394–400.

Ağız Kuruluğuna Sebep Olan Yüksek Doz Radyoaktif İyot Tedavisi Alan Hastalarda Submandibular Bezlerin Fonksiyon Değişiminin İncelenmesi

Yıl 2023, , 625 - 630, 31.12.2023
https://doi.org/10.35440/hutfd.1268830

Öz

Amaç: Bireylerin ağız kuruluğu kontrol altına alınmadığında takdirde oral sağlık sorunları ortaya çıkabilmektedir. Bununla beraber beslenme düzenleri ve yaşam kaliteleri olumsuz yönde etkilenmektedir. Bu çalışmamızda Radyoaktif iyot kullanılan hastaların submandibular bezlerin fonksiyon değişimlerini değerlendirmektir. Bununla birlikte ortaya çıkabilecek ağız kuruluğu ve diğer semptomlar açısından bilgilendirme ve yönlendirmelerin yapılmasını amaçladık
Materyal ve Metod: 2021 yılı içerisinde eğitim araştırma hastanesi nükleer tıp birimine başvuran hastalardan Diferansiye tiroid ca nedeniyle total tiroidektomi sonrasın yüksek doz (100 mCİ RAİ) RAİ alıp kliniğimizde yatmış olan hastalar çalışmamıza dahil edilmiştir. Bu hastalar içerisinden ağız kuruluğu mevcut olanların tükürük bezi sintigrafileri sistemden çıkarılarak submandibular bezlerin incelemesi yapılmıştır. Elde edilen veriler IBM SPSS 21.0 for windows programında istatistiksel olarak değerlendirilmiştir.
Bulgular: Bu çalışmada 100 mCİ alan 15 hasta tespit edilmiş ve sintigrafi ile submandibular bezlerin durumları incelenmiştir. Bu hastaların hepsinde ağız kuruluğuna rastlanmıştır. 15 hastanın 9’unda submandibular bezlerin fonksiyonu normal bulunmuştur. 6 hastada ise değişen derecelerde fonksiyon kaybı tespit edilmiştir. Nitel değişkenlerin gruplararası karşılaştırılmasında Mann Whitney U testi ile Chi-kare (χ2) testi analizi kullanıldı. Değişkenler arasındaki ilişkilerin belirlenmesinde Spearman korelasyon testi kullanıldı. Hipotezler çift yönlü olup, p≤0.05 ise istatistiksel olarak anlamlı sonuç kabul edildi.
Sonuç: Tiroid ca nedeniyle yüksek doz Radyoaktif İyot (RAİ) 131 tedavisini alan hastalarda ağız kuruluğunun geliştiği tespit edildi. Hastaların 6’sında ise submandibular bezlerin fonksiyon kaybı gözlendi. Hastalara oluşan semptomlara yönelik tavsiyelerde bulunuldu.

Kaynakça

  • 1. Moffat AK, Apajee J, Pratt NL, Blacker N, Le Blanc VT, Roughead EE. Use of medicines associated with dry mouth and dental visits in an Australian cohort. Aust Dent J. 2020;65(3):189-195.
  • 2. Scully C, Felix DH. Oral medicine update for the dental practi-tioner: dry mouth and disorders of salivation. Br Dent J. 2005;199(7):423-427.
  • 3. Fox PC. Differentiation of dry mouth etiology. Adv Dent Res. 1996;10:13-16.
  • 4. Myers N, Ferris R. Salivary Gland Disorders. New York: Spring-er Business Media; 2007. p. 2-16.
  • 5. Sonkaya E, Akbıyık SY, Bakır EP, Bakır Ş. Posterior Direkt Restorasyonlarda Nerede Başarısızlık Yaşıyoruz? Düzce Ün-iversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2021;11(2):242-249.
  • 6. Eratilla V, Kaplan İ. The effect of age on the severity of dry mouth occurring in patients receiving high dose radioactive io-dine treatment. J Health Sci Med. 2023;6(4):775-779.
  • 7. Eratilla V, Kaplan İ. Investigating the Effect of the Time Elapsed after Treatment on the Severity of Dry Mouth in Pa-tients Experiencing Dry Mouth due to Head and Neck Cancer Treatment. Mod Res Dent. 2023;7(5):777-782.
  • 8. Joanna NDY, Thomson WM. Dry mouth–an overview. Singa-pore Dent J. 20215;36(1):12-17.
  • 9. Haynes S. Medications That Cause Dry Mouth. Digestion. 2022.
  • 10. Scully C, Felix DH. Oral medicine—update for the dental prac-titioner: dry mouth and disorders of salivation. Br Dent J. 2005;199(7):423-427.
  • 11. Eratilla V. Investigation of Parotid Gland Function Changes Caused by Dry Mouth in Patients Receiving High-Dose Radio-active Iodine Treatment. J Oral Health Dent Sci. 2021;10(2):66-74.
  • 12. Su N, Marek CL, Ching V, Grushka M. Caries prevention for patients with dry mouth. J Can Dent Assoc. 2011;77(b85):1-8.
  • 13. De Jong SA. Thyroid cancer: A comprehensive guide to clinical management. Arch Pathol Lab Med. 2000;124(9):1391.
  • 14. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radi-ol). 2007;19(1):83-86.
  • 15. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition, and treatment. J Am Dent Assoc. 2003;134:61-69.
  • 16. Dodds MW, Johnson DA, Yeh CK. Health benefits of saliva: a review. J Dent Res. 2005;(33):223-233.
  • 17. Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. BMC Oph-thalmol. 2020;20(1):1-8.
  • 18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Man-agement Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid As-sociation Guidelines Task Force on Thyroid Nodules and Dif-ferentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
  • 19. Diamond-Rossi SA, Jonklaas J, Jensen RE, Kuo C, Stearns S, Esposito G, et al. Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer. J Cancer Surviv. 2020;14(6):847-857.
  • 20. Goswami S, Peipert BJ, Mongelli MN, Kurumety SK, Hele-nowski IB, Yount SE, Sturgeon C. Clinical factors associated with worse quality-of-life scores in United States thyroid can-cer survivors. Surgery. 2019;166(1):69- 74.
  • 21. Mols F, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a nor-mative sample: Results from the PROFILES Registry. Head Neck. 2018;40(10):2235–2245.
  • 22. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of sali-vary gland dysfunction in patients with thyroid cancer after ra-dioiodine treatment. Clin Nucl Med. 2002;27(11):767-771.
  • 23. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27(10):1519-27.
  • 24. Luster M, et al. Guidelines for radioiodine therapy of differen-tiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.
  • 25. Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerosto-mia symptoms. Thyroid. 2013;23(5):609–616.
  • 26. Jonklaas J, Wang H, Esposito G. Salivary function after radio-iodine therapy: poor correlation between symptoms and sali-vary scintigraphy. Front Endocrinol (Lausanne). 2015;6:100.
  • 27. Epstein JB, Stevenson-Moore P, Scully C. Management of xerostomia. J Can Dent Assoc. 1992;58:140-143.
  • 28. Epstein JB, van der Meji EH, Lunn R, Steverson-Moore P. Ef-fects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol En-dod. 1996;82:268-275.
  • 29. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:28-46.
  • 30. Walter MA, Turtschi CP, Schindler C, Minnig P, Müller-Brand J, Müller B. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med. 2007;48:1620-1625.
  • 31. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1992;33:2214-2221.
  • 32. Husson O, Mols F, Oranje WA, Haak HR, Nieuwlaat WA, Ne-tea-Maier RT, et al. Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: results of the PROFILES registry. Psycho-Oncology. 2014;23(8):946-952..
  • 33. Goldfarb M, Casillas J. Unmet information and support needs in newly diagnosed thyroid cancer: comparison of adoles-cents/young adults (AYA) and older patients. J Cancer Surviv. 2014;8(3):394–400.
Toplam 33 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Klinik Tıp Bilimleri
Bölüm Araştırma Makalesi
Yazarlar

Veysel Eratilla 0000-0002-3511-5612

İhsan Kaplan 0000-0002-5727-4702

Erken Görünüm Tarihi 22 Aralık 2023
Yayımlanma Tarihi 31 Aralık 2023
Gönderilme Tarihi 21 Mart 2023
Kabul Tarihi 20 Aralık 2023
Yayımlandığı Sayı Yıl 2023

Kaynak Göster

Vancouver Eratilla V, Kaplan İ. Ağız Kuruluğuna Sebep Olan Yüksek Doz Radyoaktif İyot Tedavisi Alan Hastalarda Submandibular Bezlerin Fonksiyon Değişiminin İncelenmesi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2023;20(3):625-30.

Harran Üniversitesi Tıp Fakültesi Dergisi  / Journal of Harran University Medical Faculty